Business Context and Reporting Period
OKYO Pharma Ltd, a foreign private issuer, filed Form 6-K on December 11, 2025. The filing announces new analyses from a recently completed Phase 2 clinical trial for urcosimod, a treatment for neuropathic corneal pain (NCP). The trial was placebo-controlled, randomized, and double-masked.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and does not contain financial statements or operational metrics.
Material Changes
The material change reported is the release of new data regarding corneal nerve structure and pain reduction in patients treated with 0.05% urcosimod. The filing does not provide comparative financial data versus prior periods.
Guidance, Outlook, and Management Commentary
- Clinical Results: Patients treated with 0.05% urcosimod demonstrated a positive reduction in neuropathic corneal pain.
- Structural Changes: Favorable changes in corneal nerve structure were observed in the treatment group, which were not observed in the placebo group.
- Outlook: The filing does not provide specific financial guidance, future trial timelines, or regulatory filing dates.
- Risks: No specific risks or contingencies are detailed in this summary text.
Key Facts for Investor Verification
- Verify the full statistical significance and detailed methodology of the corneal nerve structure analysis in the attached Exhibit 99.1.
- Confirm the specific endpoints met for the Phase 2 trial and the company's stated next steps for regulatory approval.
- Review the company's most recent Form 20-F or quarterly reports for current cash runway and burn rate, as this 6-K contains no financial data.
- Assess the competitive landscape for neuropathic corneal pain treatments in light of these structural nerve findings.